Ignacio Garrido-Laguna
( out of 82 reviews )

Ignacio Garrido-Laguna, MD, PhD, MBA

Languages spoken: Spanish, English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
1950 Circle of Hope
Salt Lake City , UT 84112
801-646-4365
Get Directions

  • Ignacio Garrido-Laguna, MD, PhD, MBA

    Professor, University of Utah School of Medicine

    Director, Phase 1 Program

    Co-leader GI Oncology Multidisciplinary Disease Group

    Expert Panel Metastatic Pancreatic Cancer: ASCO Guideline Update 2020

    Ignacio Garrido-Laguna, MD, PhD, MBA is a Professor of Oncology with tenure at the University of Utah School of Medicine and a member of the Experimental Therapeutics Program at Huntsman Cancer Institute (HCI). At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

    Dr. Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDAC). Since Dr. Garrido-Laguna arrival at HCI in 2011, accrual of PDAC patients to clinical trials has increased from less than 5% in 2011 to consistently 15%. He is PI of multiple clinical trials including novel therapies such as immunotherapies that hold promise in the treatment of this disease. His research team work in drug development in pancreatic cancer is focused on five different areas. They coined the PRIME acronym to refer to these areas (Nevala-Plagemann Nat Rev Clin Oncol 2020). P for Pathway inhibitors, R for DNA Repair agents, I for Immunotherapy, M for drugs targeting cancer metabolism and E for drugs targeting the extracellular matrix. At HCI, patients with pancreatic cancer can participate in clinical trials targeting each of these pancreatic cancer vulnerabilities. In 2018, his team and collaborators reported exceptional responses to entrectinib among patients with advanced pancreatic cancer whose tumors harbored NTRK/ROS1 fusions (Pishvaian et al JCO Precision Oncology 2018). This work was part of an early phase trial that led to FDA approval of entrectinib in patients with solid tumors with NTRK fusions (Doebele et. al Lancet Oncology 2020). In addition, this data contributed to the inclusion of NTRK testing in the recently published ASCO guidelines for metastatic pancreatic cancer (Sohal et al. JCO 2020). While NTRK fusions are very rare events in PDAC (<0.5%), genetic testing to them may render new treatment opportunities for a subset of patients with this recalcitrant disease. In addition, translational work at Huntsman Cancer institute from Aria Vaishnavi (Martin McMahon lab) recently demonstrated that TPR-NTRK fusions were oncogenic in PDAC. More importantly, vertical inhibition of NTRK pathway with entrectinib plus cobimetinib led to sustained inhibition of the pathway and durable responses in xenografts (Vaishnavi et. al Cell Reports 2020).

    Dr. Garrido-Laguna is member of the GI Committee at SWOG. In collaboration with Dr. Sohal from University of Cincinnatti and Dr.Beatty from University of Pennsylvania, he is conducting a translational medicine study using samples from SWOG1505 to evaluate immunologic predictors of therapeutic response to neoadjuvant therapy for pancreatic cancer.

    He is a Principal Investigator in more than 15 phase 1 clinical trials. This includes an ongoing investigator initiated study to evaluate a RAS signature in patients with KRAS positive metastatic colorectal cancer treated with Folfiri plus a MEK inihibitor.

    Dr. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain. He then completed his internship and residency in Internal Medicine-Medical Oncology at Hospital Universitario 12 de Octubre in Madrid, Spain.

    Before joining HCI, Dr. Garrido-Laguna was a clinical fellow in the Phase I program at the University of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. While at Hopkins, he worked extensively in patient derived xenografts. His research showed that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy in pancreatic cancer.

    Pancreatic trials decision tree: https://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials/images/pancreatic-cancer-slide.jpg

    Colorectal trials decision tree: https://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials/images/colorectal-cancer-slide.jpg

    GI trials at Hunstman Cancer Institute: http://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials/find-clinical-trials-at-hci/gastrointestinal.php

    Avatar mice https://en.wikipedia.org/wiki/Mouse_avatars

    Specialties

    Board Certification

    Ministry of Science and Education of Spain (Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)
    European Society for Medical Oncology
    National Board of Medical Examiners
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 82 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER

    Dr. Garrido is a excellent Doctor

    HUNTSMAN CANCER CENTER

    What an engaging and professional doctor. You feel he is listening, is genuinely concerned and wants the most positive outcome for all his patients. Thanks for a great experience

    HUNTSMAN CANCER CENTER

    Dr Garrido covered everything and made sure I knew the follow up needed. He has been great during the several months he managed my care.

    HUNTSMAN CANCER CENTER

    Sweet good man, with not good news for me, but he was kind and attentive.

    HUNTSMAN CANCER CENTER

    Overall the assistance and Doctors are awesome!

    HUNTSMAN CANCER CENTER

    great

    HUNTSMAN CANCER CENTER

    All the staff Dr. were very helpful and understanding.

    HUNTSMAN CANCER CENTER

    The care Dr. Garrido-Laguna has been exceptional!

    HUNTSMAN CANCER CENTER

    This was my first visit. My questions were answered as best they could be, and I'm hoping all will be well as I proceed down this health challenge. I am grateful for the knowledgeable staff at Huntsman

  • Ignacio Garrido-Laguna, MD, PhD, MBA

    Professor, University of Utah School of Medicine

    Director, Phase 1 Program

    Co-leader GI Oncology Multidisciplinary Disease Group

    Expert Panel Metastatic Pancreatic Cancer: ASCO Guideline Update 2020

    Ignacio Garrido-Laguna, MD, PhD, MBA is a Professor of Oncology with tenure at the University of Utah School of Medicine and a member of the Experimental Therapeutics Program at Huntsman Cancer Institute (HCI). At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

    Dr. Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDAC). Since Dr. Garrido-Laguna arrival at HCI in 2011, accrual of PDAC patients to clinical trials has increased from less than 5% in 2011 to consistently 15%. He is PI of multiple clinical trials including novel therapies such as immunotherapies that hold promise in the treatment of this disease. His research team work in drug development in pancreatic cancer is focused on five different areas. They coined the PRIME acronym to refer to these areas (Nevala-Plagemann Nat Rev Clin Oncol 2020). P for Pathway inhibitors, R for DNA Repair agents, I for Immunotherapy, M for drugs targeting cancer metabolism and E for drugs targeting the extracellular matrix. At HCI, patients with pancreatic cancer can participate in clinical trials targeting each of these pancreatic cancer vulnerabilities. In 2018, his team and collaborators reported exceptional responses to entrectinib among patients with advanced pancreatic cancer whose tumors harbored NTRK/ROS1 fusions (Pishvaian et al JCO Precision Oncology 2018). This work was part of an early phase trial that led to FDA approval of entrectinib in patients with solid tumors with NTRK fusions (Doebele et. al Lancet Oncology 2020). In addition, this data contributed to the inclusion of NTRK testing in the recently published ASCO guidelines for metastatic pancreatic cancer (Sohal et al. JCO 2020). While NTRK fusions are very rare events in PDAC (<0.5%), genetic testing to them may render new treatment opportunities for a subset of patients with this recalcitrant disease. In addition, translational work at Huntsman Cancer institute from Aria Vaishnavi (Martin McMahon lab) recently demonstrated that TPR-NTRK fusions were oncogenic in PDAC. More importantly, vertical inhibition of NTRK pathway with entrectinib plus cobimetinib led to sustained inhibition of the pathway and durable responses in xenografts (Vaishnavi et. al Cell Reports 2020).

    Dr. Garrido-Laguna is member of the GI Committee at SWOG. In collaboration with Dr. Sohal from University of Cincinnatti and Dr.Beatty from University of Pennsylvania, he is conducting a translational medicine study using samples from SWOG1505 to evaluate immunologic predictors of therapeutic response to neoadjuvant therapy for pancreatic cancer.

    He is a Principal Investigator in more than 15 phase 1 clinical trials. This includes an ongoing investigator initiated study to evaluate a RAS signature in patients with KRAS positive metastatic colorectal cancer treated with Folfiri plus a MEK inihibitor.

    Dr. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain. He then completed his internship and residency in Internal Medicine-Medical Oncology at Hospital Universitario 12 de Octubre in Madrid, Spain.

    Before joining HCI, Dr. Garrido-Laguna was a clinical fellow in the Phase I program at the University of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. While at Hopkins, he worked extensively in patient derived xenografts. His research showed that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy in pancreatic cancer.

    Pancreatic trials decision tree: https://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials/images/pancreatic-cancer-slide.jpg

    Colorectal trials decision tree: https://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials/images/colorectal-cancer-slide.jpg

    GI trials at Hunstman Cancer Institute: http://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials/find-clinical-trials-at-hci/gastrointestinal.php

    Avatar mice https://en.wikipedia.org/wiki/Mouse_avatars

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Oncology
    Board Certification
    Ministry of Science and Education of Spain (Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)
    European Society for Medical Oncology
    National Board of Medical Examiners
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Professional Medical Medicine - Universidad de Navarra M.D.
    Residency Internal Medicine-Medical Oncology - Hospital Universitario 12 de Octubre Resident
    Postdoctoral Fellowship Drug Development in Gastrointestinal Oncology - The Sidney Kimmel Comprehensive Cancer at Johns Hopkins Postdoctoral Fellow
    Fellowship Investigational Cancer Therapeutics - University of Texas MD Anderson Cancer Center Clinical Fellow
    Doctoral Training Validation of response to gemcitabine in freshly generated pancreatic cancer xenografts - Universidad de Navarra Ph.D.
    Post Graduate Training Business Administration - David Eccles School of Business University of Utah MBA

    Selected Publications

    Journal Article

    1. Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362. (Read full publication)
    2. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M (2010). Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer, 103(5), 649-55. (Read full publication)
    3. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2012). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8. (Read full publication)
    4. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R (2014). Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 120(14), 2164-73. (Read full publication)
    5. Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM (2017). Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 123(19), 3816-3824. (Read full publication)
    6. Solomon BL, Garrido-Laguna I (2018). TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother, 67(11), 1659-1667. (Read full publication)
    7. Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL (2016). Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clin Neurol Neurosurg, 149, 11-4. (Read full publication)
    8. Kalasekar SM, Garrido-Laguna I, Evason K (2021). Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 73(6), 2591-2593. (Read full publication)
    9. Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong D (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. International journal of cancer, 145(7), 1798-1808. (Read full publication)
    10. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational new drugs, 31(5), 1257-64. (Read full publication)
    11. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma (2019). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Investigational new drugs, 37(3), 482-489. (Read full publication)
    12. Garrido-Laguna I, Ponz M, Espinos (2007). Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?. Journal of clinical oncology, 25(9), 1149; author reply 1149-51. (Read full publication)
    13. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock (2010). Response of histiocytoses to imatinib mesylate: fire to ashes. Journal of clinical oncology, 28(31), e633-6. (Read full publication)
    14. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock (2012). PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Journal of clinical oncology, 30(8), 777-82. (Read full publication)
    15. Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru (2018). Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of clinical oncology, 36(24), 2545-2556. (Read full publication)
    16. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru (2020). Metastatic Pancreatic Cancer: ASCO Guideline Update. Journal of clinical oncology, JCO2001364. (Read full publication)
    17. Garrido-Laguna I, Fernandez Hidalgo O, Garcia Foncillas (2007). MRI evaluation of breast cancer. The New England journal of medicine, 357(2), 191; author reply 193. (Read full publication)
    18. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna (2021). Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 50(6), 773-787. (Read full publication)
    19. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. (Read full publication)
    20. Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao (2017). Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Annals of surgical oncology, 24(13), 4001-4008. (Read full publication)
    21. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao (2021). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Annals of surgical oncology, 28(2), 663-675. (Read full publication)
    22. Foth M, Garrido-Laguna I, Kinsey C (2021). Therapeutic Targeting of Autophagy in Pancreatic Cancer. Surgical oncology clinics of North America, 30(4), 709-718. (Read full publication)
    23. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock (2010). Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clinical cancer research, 16(15), 4031-7. (Read full publication)
    24. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo (2011). Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clinical cancer research, 17(17), 5793-800. (Read full publication)
    25. Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster H (2021). Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical cancer research, 27(23), 6314-6322.
    26. Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster H (2021). Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical cancer research, 27(23), 6314-6322. (Read full publication)
    27. Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma (2021). A Phase 1a/b Open'Label, Dose'Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical cancer research, (Read full publication)
    28. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale M (2020). Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical cancer research, 26(21), 5579-5587. (Read full publication)
    29. Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife C (2019). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. Journal of gastrointestinal surgery, 23(7), 1401-1413. (Read full publication)
    30. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock (2011). Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. The oncologist, 16(3), 327-35. (Read full publication)
    31. Liang WS, Vergilio J, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku (2019). Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. The oncologist, 24(2), 219-228.
    32. Gan HK, Millward M, Jalving M, Garrido-Laguna I, Lickliter JD, Schellens JHM, Lolkema MP, Van Herpen CLM, Hug B, Tang L, O'Connor-Semmes R, Gagnon R, Ellis C, Ganji G, Matheny C, Drilon (2021). A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. The oncologist, 26(10), e1844-e1853. (Read full publication)
    33. Affolter KE, Hellwig S, Nix DA, Bronner MP, Thomas A, Fuertes CL, Hamil CL, Garrido-Laguna I, Scaife CL, Mulvihill SJ, Underhill H (2021). Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia (New York, N.Y.), 23(9), 859-869. (Read full publication)
    34. Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang Y (2017). A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC cancer, 17(1), 646. (Read full publication)
    35. Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang Y (2017). A Phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC cancer, Sep 12; 17(1), 646.
    36. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 21(2), 271-282. (Read full publication)
    37. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin B (2011). Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer biology & therapy, 12(7), 598-609. (Read full publication)
    38. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock (2012). Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clinical colorectal cancer, 11(4), 297-303. (Read full publication)
    39. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo (2011). Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Molecular cancer therapeutics, 10(1), 3-8. (Read full publication)
    40. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock (2011). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Molecular cancer therapeutics, 10(3), 558-65. (Read full publication)
    41. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular cancer therapeutics, 10(8), 1311-6. (Read full publication)
    42. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock (2016). Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Molecular cancer therapeutics, 15(4), 533-47. (Read full publication)
    43. Martin-Santamaria S, Rodriguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, Lopez-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos (2008). New scaffolds for the design of selective estrogen receptor modulators. Organic & biomolecular chemistry, 6(19), 3486-96. (Read full publication)
    44. Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt R (2014). Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clinical gastroenterology and hepatology, 12(12), 2078-84.e1-2. (Read full publication)
    45. Garrido-Laguna I, Amador ML, Ruiz J, Cortés-Funes (2009). Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clinical & translational oncology, 11(3), 183-5. (Read full publication)
    46. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass D (2018). NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16(4), 359-369. (Read full publication)
    47. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. Journal of the National Comprehensive Cancer Network, 19(5), 478-482. (Read full publication)
    48. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski L (2021). Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(3), 329-359. (Read full publication)
    49. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski L (2020). NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. Journal of the National Comprehensive Cancer Network, 18(7), 806-815. (Read full publication)
    50. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski L (2019). Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(9), 1109-1133. (Read full publication)
    51. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah (2014). Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discovery medicine, 18(101), 323-30. (Read full publication)
    52. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah (2014). Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discovery medicine, 18(101), 331-9. (Read full publication)
    53. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah (2015). Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discovery medicine, 19(103), 101-8. (Read full publication)
    54. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah (2015). Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discovery medicine, 19(103), 109-16. (Read full publication)
    55. Solomon BL, Garrido-Laguna (2018). Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future oncology (London, England), 14(10), 947-962. (Read full publication)
    56. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock (2011). PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PloS one, 6(7), e22769. (Read full publication)
    57. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock (2012). KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PloS one, 7(5), e38033. (Read full publication)
    58. Nix DA, Hellwig S, Conley C, Thomas A, Fuertes CL, Hamil CL, Bhetariya PJ, Garrido-Laguna I, Marth GT, Bronner MP, Underhill H (2020). The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. PloS one, 15(2), e0229063. (Read full publication)
    59. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock (2011). Novel therapeutic targets in non-small cell lung cancer. Journal of thoracic oncology, 6(9), 1601-12. (Read full publication)
    60. Tao R, Lloyd S, Burt L, Whisenant J, Garrido-Laguna I, Das (2017). Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. Current colorectal cancer reports, 13(2), 175-82.
    61. Reese Z, Patel S, Stenehjem DD, Garrido-Laguna (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. Journal of gastrointestinal cancer, 45 Suppl 1, 278-81. (Read full publication)
    62. Garrido-Laguna I, Hidalgo (2015). Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nature reviews. Clinical oncology, 12(6), 319-34. (Read full publication)
    63. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna (2020). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature reviews. Clinical oncology, 17(2), 108-123. (Read full publication)
    64. Patel SB, Gill D, Garrido-Laguna (2015). Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and therapy, 9, 75-86. (Read full publication)
    65. Iyengar S, Nevala-Plagemann C, Garrido-Laguna (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Therapeutic advances in medical oncology, 13, 17588359211045861. (Read full publication)
    66. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock (2012). PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget, 3(12), 1566-75. (Read full publication)
    67. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku (2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 7(41), 67521-67531. (Read full publication)
    68. Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd (2018). Large database utilization in health outcomes research in pancreatic cancer: an update. Journal of gastrointestinal oncology, 9(6), 996-1004. (Read full publication)
    69. Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd (2018). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. Journal of gastrointestinal oncology, 9(6), 1014-1026. (Read full publication)
    70. Au TH, Wang K, Stenehjem D, Garrido-Laguna (2017). Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. Journal of gastrointestinal oncology, 8(3), 387-404.
    71. Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon (2020). Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell reports, 32(5), 107994. (Read full publication)
    72. Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd (2020). The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer medicine, 9(5), 1703-1711. (Read full publication)
    73. Florou V, Puri S, Garrido-Laguna I, Wilky B (2021). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Annals of translational medicine, 9(12), 1035. (Read full publication)
    74. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock (2014). A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 1(10), 614-623. (Read full publication)
    75. Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma (2015). N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience, 2(3), 285-93. (Read full publication)
    76. Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd (2018). Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO open, 3(1), e000282. (Read full publication)
    77. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO open, 3(5), e000386. (Read full publication)
    78. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO open, 4(4), e000539.
    79. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO precision oncology,
    80. Stenehjem DD, Cavalieri CC, Swanson E, Solomon B, Whisenant J, Tran D, Weis J, Gilcrease GW, Sharma S, Garrido-Laguna (2018). Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series. 1(1), 1-6.
    81. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. Journal of the National Comprehensive Cancer Network, 20(3), 1-8. (Read full publication)
    82. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna (2022). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. Journal of the National Comprehensive Cancer Network, 20(2), 144-150. (Read full publication)
    83. Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo (2018). Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO precision oncology, 2, 1-7. (Read full publication)
    84. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer, 54(2), 492-500. (Read full publication)
    85. Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin J (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for immunotherapy of cancer, 10(3), (Read full publication)
    86. Florou V, Garrido-Laguna (2022). Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer. Current oncology reports,
    87. Harding JJ, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, Hooper AT, Kamperschroer C, Max SI, Moreau A, Shannon M, Wong GY, Hong D (2022). A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Frontiers in immunology, 13, 845417. (Read full publication)
    88. Pauley K, Koptiuch C, Greenberg S, Kohlmann W, Jeter J, Colonna S, Werner T, Kinsey C, Gilcrease G, Weis J, Whisenant J, Florou V, Garrido-Laguna (2022). Discrepancies between tumor genomic profiling and germline genetic testing. ESMO open, 7(14), 100526.
    89. Powderly JD, Klempner SJ, Naing A, Bendell J, Garrido-Laguna I, Catenacci DVT, Taylor MH, Lee JJ, Zheng F, Zhou F, Gong X, Gowda H, Beatty G (2022). Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study. The oncologist, 27(11), 905-e848. (Read full publication)
    90. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC cancer, 22(1), 1054. (Read full publication)
    91. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski (2022). Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(10), 1139-1167. (Read full publication)
    92. Florou V, Garrido-Laguna (2020). Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. Journal of immunotherapy and precision oncology, 3(3), 137-139. (Read full publication)
    93. Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong D (2022). Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. The New England journal of medicine, (Read full publication)
    94. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna (2023). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. Journal of the National Comprehensive Cancer Network, 21(3), 257-264. (Read full publication)
    95. Beatty GL, Delman D, Yu J, Liu M, Li JH, Zhang L, Lee JW, Chang RB, Bahary N, Kennedy EP, Wang-Gillam A, Rossi GR, Garrido-Laguna (2023). Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration. Clinical cancer research, 29(17), 3514-3525. (Read full publication)
    96. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna (2023). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clinical cancer research, 29(17), 3408-3417. (Read full publication)
    97. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for immunotherapy of cancer, 11(8), (Read full publication)
    98. Rodon Ahnert J, Tan DS, Garrido-Laguna I, Harb W, Bessudo A, Beck JT, Rottey S, Bahary N, Kotecki N, Zhu Z, Deng S, Kowalski K, Wei C, Pathan N, Laliberte RJ, Messersmith W (2023). Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. ESMO open, 8(4), 101584. (Read full publication)
    99. Moraitis AM, Rose NB, Johnson AF, Dunston ER, Garrido-Laguna I, Hobson P, Barber K, Basen-Engquist K, Coletta A (2023). Feasibility and acceptability of an mHealth, home-based exercise intervention in colorectal cancer survivors: A pilot randomized controlled trial. PloS one, 18(6), e0287152. (Read full publication)
    100. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman (2023). Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(6), 653-677. (Read full publication)
    101. Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, Kamal S, Marzullo L, De Marco M, Falco A, Genovese A, Adler JM, De Laurenzi V, Adler DG, Affolter KE, Garrido-Laguna I, Scaife CL, Turco MC, Mulvihill S (2023). Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO clinical cancer informatics, 7, e2200160. (Read full publication)
    102. Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla (2022). A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer research communications, 2(11), 1326-1333. (Read full publication)
    103. Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Lee J, Affolter K, Mulvihill SJ, Beg MS, Wang-Gillam A, Wade JL 3rd, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty G (2024). Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 166(6), 1114-1129. (Read full publication)
    104. Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler ME, Hütter-Krönke ML, Perotti A, Juif PE, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-ß monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for immunotherapy of cancer, 11(11), (Read full publication)
    105. Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson (2023). Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine, 67, 102376. (Read full publication)
    106. Nevala-Plagemann C, Garrido-Laguna (2024). NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?. Nature reviews. Clinical oncology, 21(8), 567-568. (Read full publication)
    107. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones (2024). Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(2 D), (Read full publication)
    108. Faber EB, Krause HB, Amin K, Walker P, Hosein PJ, Shields AF, Lenz HJ, Prakash A, Goel S, Oberley M, Malleo G, Luchini C, Hwang J, Florou V, Garrido-Laguna I, Lou (2024). Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets. JCO precision oncology, 8, e2300595. (Read full publication)
    109. Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer (2024). Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers, 16(7), (Read full publication)
    110. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. Journal of gastrointestinal oncology, 14(6), 2637-2643.
    111. Li D, Loriot Y, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson S. Burgoyne A (2023). Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial. EClinicalMedicine, 67(102376),
    112. Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Lee J, Affolter K, Mulvihill SJ, Beg MS, Wang-Gillam A, Wade JL 3rd, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty GL (2024). Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 166(6), 1114-1129.
    113. Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA network open, 8(1), e2453588. (Read full publication)
    114. Christopher Nevala-Plagemann , Thierry Conroy , Garrido-Laguna (2024). Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer; evidence beyond NAPOLI 3'. National Library of Medicine. Current Bibliographies in Medicine, 902,
    115. Ben Tran, Mark Voskoboynik , Johanna Bendell, Martin Gutierrez, Charlotte Lemech, Daphne Day, Sophia Frentzas, Garrido-Laguna I, Nathan Standifer, Fujun Wang, Charles Ferte, Yue Wang, Mayukh Das, Benedito A Carneir (2024). A phase one study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. . National Library of Medicine. Current Bibliographies in Medicine, 16(11), 759-774.
    116. Al B Benson, Alan P Venook, Mohamed Adam, George Chang, Yi-Jen Chen, Kristen K Ciombor, Stacey A Cohen, Harry S Cooper, Dustin Deming, Garrido-Laguna I, Jean L Grem, Paul Haste, J Randolph Hecht, Sarah Hoffe, Steven Hunt, Hisham Hussan, Kimberly L Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K Maratt, Wells A Messersmith, Jeffrey Meyerhardt, Eric D Miller, Mary F Mulcahy, Steven Nurkin, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, Benjamin Shogan, John M Skibber, Constantinos T Sofocleous, Anna Tavakkoli, Christopher G Willett, Christina Wu, Frankie Jones , Lisa Gursk (2024). JNCCN Guidelines&reg; Insights: Rectal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(6), 366-375.
    117. Pauley K, Koptiuch C, Greenberg S, Kohlmann W, Jeter J, Colonna S, Werner T, Kinsey C, Gilcrease G, Weis J, Whisenant J, Florou V, Garrido-Laguna (2022). Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study. The oncologist, 27(11), 905-e848.
    118. Miotke L, Norton C, Rubnitz Z, Florou V, Nevala-Plagemann C, Garrido-Laguna (2025). Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer. ESMO open, 10(9), 105768. (Read full publication)
    119. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski (2024). NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(6), 366-375. (Read full publication)
    120. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. Journal of gastrointestinal oncology, 14(6), 2637-2643. (Read full publication)

    Review

    1. Garrido-Laguna I, Hidalgo M, Kurzrock (2011). The inverted pyramid of biomarker-driven trials. Nature reviews. Clinical oncology, 8(9), 562-6. (Read full publication)
    2. Gouda MA, Ballesteros PA, Garrido-Laguna I, Rodon (2025). Efficacy assessment in phase I clinical trials: endpoints and challenges. Annals of oncology, 36(5), 507-519. (Read full publication)

    Book Chapter

    1. Janku F, Garrido-Laguna I, Kurzrock (2011). Early-Phase Cancer Clinical Trials: Are the Goals Scientific of Therapeutic?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,
    2. Garrido-Laguna (2009). Targeted Therapies.
    3. Garrido-Laguna (2006). Emergencies in Oncology.

    Case Report

    1. Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna (2017). Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy, 9(10), 797-804.
    2. Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder N (2017). A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. ACG case reports journal, 4, e34. (Read full publication)
    3. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO precision oncology, 4, (Read full publication)
    4. Rubnitz Z, Nevala-Plagemann C, Florou V, Garrido-Laguna (2025). Gemcitabine-induced myositis in a patient with pancreatic cancer. BMJ case reports, 18(1), (Read full publication)

    Letter

    1. Garrido-Laguna I, Janku (2012). Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?. Journal of clinical oncology, 30(8), 892-3. (Read full publication)
    2. Nevala-Plagemann C, Conroy T, Garrido-Laguna (2024). Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'. Nature reviews. Clinical oncology, 21(12), 902. (Read full publication)

    Abstract

    1. D. Stenehjem, S. Gupta, M. Wade, G. Gilcrease, I. Garrido-Laguna, J.R. Weis, J. Whisenant, S. Sharma (1 Oct 2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies [Abstract]. Ann Oncol, 27(suppl_6), 1071.
    2. Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Fu S, Moulder SL, Luthra R, Lee JJ, Tsimberidou AM, Kurzrock (2011). Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. Journal of clinical oncology, 29(15_suppl), 10507. (Read full publication)
    3. Garrido-Laguna I, Kurzrock R, Wheler JJ, Falchook GS, Piha-Paul SA, Fu S, Naing A, Hinojosa C, Mistry R, Scamardo A, Culotta KS, Ekmekcioglu S, Wen S, Camacho LH, Ivy SP, Hong D (2011). Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. Journal of clinical oncology, 29(15_suppl), 3065. (Read full publication)
    4. Shiven B. Patel, Danielle Tometich, Zachary L Reese, Sunil Sharma, Ignacio Garrido-Lagun (2015). Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002 through 2012. Presented at the 2015 Gastrointestinal Cancers Symposium. Journal of clinical oncology, 33(suppl 3 abstr 687),
    5. Zachary L Reese, Danielle Tometich, Shiven B. Patel, Sunil Sharma, Ignacio Garrido-Lagun (2015). Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012. Presented at the 2015 Gastrointestinal Cancers Symposium., Abstract 311. Journal of clinical oncology, 33(suppl 3), abstr 311.
    6. H Park, I Garrido-Laguna, A Naing, S Fu, GS Falchook, SA Piha-Paul, JJ Wheler, DS Hong, V Subbiah, AM Tsimberidou, AO Kaseb, Y Oki, R Zinner, S Patel, V Velez Bravo, MA Fanale, F Meric Bernstam, R Kurzrock, F Janku (2015). Phase 1 study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. ASCO Annual Meeting May 29-June 2,2015. Journal of clinical oncology, 33, 2015(suppl; abstr 2584)),
    7. K Wang, A Johnson, I Garrido-Laguna, J Chmielecki, R Yelensky, D Lipson, JA Elvin, JA Vergilio, SA Ali, V Miller, PJ Stephens, JS Ros (2015). Amplification of CRKL in human cancer: a rare event associated with potential sensitivity to targeted therapy. ASCO Annual Meeting May 29-June 2,2015. Abstract Number: 1526. Journal of clinical oncology, 33, 2015(suppl; abstr 1526),
    8. Garrido-Laguna I, Krop IE, Burris H, Hamilton EP, Braiteh FS, Weise A, Abu-Khalaf MM, Zopf C, Lakshminarayanan M, Holland JS, Baffa R, Hong D (2017). A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer. Presented at the 2017 ASCO Annual Meeting on June 5, 2017. Journal of clinical oncology, 35(suppl; abstr 2511),
    9. Garrido-Laguna I, Janku F, Falchook GS, Naing A, Fu S, Wheler J, Tsimberidou AM, Hong DS, Kurzrock R (2011). Retrospective study to elucidate a K-ras phenotype in patients with colorectal cancer.PMID: 27985389. Journal of clinical oncology, 29(4_suppl), 462.
    10. Garrido-Laguna I, Rudek M, Tan A, Uson M, Iacobuzio-Donahue C, Angenendt M, Jimeno A, Laheru D, Barret M, Hidalgo (2009). Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine.PMID: 27964189. Journal of clinical oncology, 27(15_suppl), 4612.
    11. Tan A, Jimeno A, Garrido-Laguna I, Uson M, De Oliveira E, Wilson A, Rubio-Viqueira B, Rajeshkumar NV, Hidalgo (2009). Use of amolecular mimicry approach to identify effective agents in pancreatic cancer.PMID: 27964150. Journal of clinical oncology, 27(15_suppl), 4603.
    12. Hidalgo M, Garrido-Laguna I, Uson M, De Oliveira E, Schulick R, Hruban RH, Maitra A, Jimeno A, Rubio-Viqueira B, Rajeshkumar N (2009). Activity of gemcitabine in direct patient-derived xenografts and clinical outcome: Validation of an in vivo model for drug development.PMID: 27962716. Journal of clinical oncology, 27(15_suppl), 4528.
    13. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna (2019). Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab. Journal of clinical oncology, 4(4), e000539.
    14. Gruhl J, Francis SR, Tao R, Solomon BL, Nevala-Plagemann CD, Garrido-Laguna I, Lloyd (2019). The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.Presented ASCO 2019 Gastrointestinal Cancers Symposium. Journal of clinical oncology, 37(2019), suppl 4 abstr 419.
    15. Pelzer U, Bendell JC, Womack MS, Bahary N, Macarulla T, Borazanci EH, Levy DE, Mo G, Ramage SC, Garrido-Laguna (2019). A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.Presented AASCO 2019 Gastrointestinal Cancers Symposium. Journal of clinical oncology, 37(2019), suppl 4; abstr 330.
    16. DS Hong, I Garrido-Laguna, IE Krop, V Subbiah, TL Werner, CM Cotter, EP Hamilton, K Velastegui, D Xuan, R Bugarini, A Gollerkeri, HA Burri (2015). First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. ASCO Annual Meeting May 29-June 2,2015 (Abst. # to be released on May 13th).
    17. WS Liang, B Salhia, A Helland, S Sekar, I Garrido-Laguna, M Fanale, Y Oki, JR Westin, RE Davis, F Meric-Bernstam, F Jank (2015). Identification of mutations in histrone modification genes in Hodgkin lymphoma. AACR 106th Annual Meeting, April 18-22 (LB-176).
    18. Reynolds K., Juric D., Baselga J.,..., Garrido-Laguna I,..., Bang, Y. et al (2014). A Phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer or HER2-overexpressing metastatic breast or gastric cancer.
    19. Shepard D, Bruce J, Garrido-Laguna I, et a (2014). Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.
    20. Bendell JC, Pelzer U, Womack MS, Borazanci EH, Bahary N, Garrido-Laguna I, Maur M, Prater T, Levy DE, Cronier D, Ramage S, Macarulla T, Cannon (2018). A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.
    21. Janku F, Garrido-Laguna I, Velez-Bravo V et al (2013). Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. 122(21), 3048.
    22. Janku F, Garrido-Laguna I, Tsimberidou A, et al (2011). Screening for PIK3CA Mutations, PTEN Loss and RAS/RAF mutations in Early-Phase Protocols with PI3K/mTOR Pathway Inhibitors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 10507).
    23. Janku F, Tsimberidou A, Garrido-Laguna I et al (2010). Screening for PIK3CA, Ras and Raf mutations in trials with PI3K/Akt/mTOR signaling pathway inhibitors. 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics¿, Berlin.
    24. Garrido-Laguna I, Kurzrock R, Falchook GS, et al (2011). Dual inhibition of VEGF pathway: Phase 1 trial of bevacizumab and cediranib in advanced solid tumors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 3057).
    25. Nevala-Plagemann CD, Francis S, Cavalieri CC, LLoyd S, Garrido-Laguna I (2018). The effect of adjuvant chemotherapy in patients without local nodal metastases following neoadjuvant chemoradiotherapy and esophagectomy for locally advanced esophageal cancer.
    26. Francis S, Nevala-Plagemann CD, Cavalieri CC, Lloyd S, Garrido-Laguna I (2018). Postoperative chemotherapy in patients who are pN+ following neoadjuvant chemoradiation for locally advanced esophageal cancer.
    27. Garrido-Laguna I, Tometich D., Hu Nan, Boucher K, Sharma (2014). N of 1 Case Reports of Exceptional Responders Among Pancreatic Cancer Patients Enrolled in First-in-man studies from 2002 through 2012. Pancreatic Cancer: Innovation in Research and Treatment 2014 New Orleans, abst # B93. 2(3), 285-293.
    28. Garrido-Laguna I, Janku F, Falchook GS, et al (2011). KRAS mutations in colorectal cancer may predict a pattern of organ-specific metastasis. AACR 102nd Annual Meeting, April 2-6, 2011; Orlando, FL. (Abstract # 2264).
    29. Janku F, Garrido-Laguna I, Hong DS. et al (2011). Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. AACR 102nd Annual Meeting 2011; April 2-6, 2011; Orlando, FL (Abstract #1279).
    30. Garrido-Laguna I, Janku F, Falchook GS, et al (2010). Clinical outcomes of patients with advanced head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. AACR 101st Annual Meeting, April 17-21, 2010, Washington, DC. (Abst #2773).
    31. Janku F, Garrido-Laguna I, Hong D, Tsimberidou A, et al (2009). PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. B134). Boston.
    32. Rajeshkumar NV, De Oliveira E, Ottenhof N, Garrido-LagunaI I, et al (2009). MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A251). Boston.
    33. Mishra A, Feldmann G, Garrido-Laguna I, Dadon T, Strock C, Bannerji R, Hidalgo M, Maitra A, Nelkin (2009). SCH727965, a novel potent cyclin dependent kinase inhibitor, inhibits pancreatic tumor growth and Ras-mediated tumorigenic signaling. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A243). Boston.
    34. Hidalgo M, Strawn S, Wick M, Rajeshkumar NV, Garrido-Laguna I, Sidranski D, Bruckheimer (2009). From mice to men: Guiding cancer treatment through Personalized Tumorgraft models results in prolongued clinical responses in patients with refractory advanced cancers and discovery of novel predictive biomarkers. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A19). Boston.
    35. Maitra A, Rajeskhumar NV, Rudek M, Garrido-Laguna I, Laheru D, Iglesias J, Desai N, Von Hoff D, Hidalgo (2009). Nab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic models. C246. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. C246). Boston.
    36. Garrido-Laguna I, Tan AC, Villarroel MC, Angenendt M, Pastori W, Rajeshkumar NV, Ciomei M, Jimeno A, Rubio-Viqueira B, Hidalgo (2009). Activity of PHA-848125 in pancreatic cancer xenografts is related to downregulation of S6 via p53 pathway. AACR 100th Annual Meeting in Denver (Permanent abst number 1798).
    37. Villaroel MC, Tan AC, Garrido-Laguna I, Rubio-Viqueira B, De Oliveira E, Rajeshkumar NV, Jimeno A, Hidalgo (2009). Orthotopic cancer models are better predictors of clinical response than s.c. models. AACR 100th Annual Meeting in Denver (Permanent abst number 2320).
    38. Nathan Bahary, Ignacio Garrido-Laguna, Andrea Wang-Gillam, Asha Nyak-Kapoor, Eugene Kennedy, Nicholas N. Vahanian, Charles J. Lin (2016). Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.
    39. Garrido-Laguna I, McGregor K, Wade M, et al (2012). Testing targeted demethylation to overcome resistance to epidermal growth factor receptor (EGFR) blocking agents in wild-type (wt) KRAS metastatic colorectal cancer patients (mCRC). 2012 ASCO Annual Meeting, Chicago, IL. (Abstract number 3057). 30(15_suppl), 3057.
    40. Samadder NJ, Curtin K, Wong J, Pappas L, Tuohy T, Mineau G, Smith K, Pimentel R, Boucher K, Garrido-Laguna I, Provenzale D, Burt, (2013). Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah. Abs P599, ACG Annual Meeting, San Diego 2013.
    41. Cavalieri CC, Swanson E, Whisenant JR, Weis JR, Gilcrease GW, Stenehjem DD, Sharma S, Garrido-Laguna (2017). Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. Presented at the 2017 Gastrointestinal Cancers Symposium, Poster Session C: Cancers of the Colon, Rectum, and Anus. 35(suppl 4S; abstract 792),
    42. Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I (2018). Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.
    43. Swords DS, Garrido-Laguna I, Mulvihill SJ, Stoddard GJ, Firpo MA, Scaife C (2018). Association of adjuvant chemotherapy with overall survival in resected pancreatic adenocarcinoma previously treated with neoadjuvant therapy.
    44. Sharma S, Moore KN, Mettu NB, Garrido-Laguna I, Ulahannan SV, Khemka V, Kapoun A, Faoro L, Bendell (2018). Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with lg and ITIM domains (TIGIT) antibody, in advanced solid tumors.
    45. Bahary N, Wang-Gillam A, Haraldsdottir S, Somer BG, Lee JS, O'Rourke MA, Nayak-Kapoor A, Beatty GL, Liu M, Delman D, Rossi GR, Kennedy EP, Vahanian NN, Link CJ, Garrido-Laguna (2018). Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
    46. Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Lew DL, Lowy AM, Hochster H (2019). Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. 37(2019), (suppl; abstr 4014).
    47. Siena S, Demetri G, Doebele R, Chae Y, Conkling P, Garrido-Laguna I, Garrido P, Rolfo C, Sigal D, Eng S, Simmons B, Ye C, Ciardiello (2019). Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). 2019(Abstract #0-024),
    48. Vaishnavi A, Scherzer M, Kinsey C, Garrido-Laguna I, McMahon (2019). MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance to Entrectinib in a New Preclinical Model of TPR-NTRK1 Driven Pancreatic Cancer.
    49. Parsons M, Tao R, Lloyd S, Johnson SB, Scaife CL, Garrido-Laguna I, Varghese (2020). Refusal of surgery results in inferior survival in esophageal cancer. 38(2020), (suppl 4; abstr 364).
    50. Pauley K, Koptiuch C, Greenberg S, Gammon A, Nevala-Plagemann C, Vagher J, Espinel W, Gilcrease GW, Kohlmann W, Garrido-Laguna (2020). Case series examining somatic test results for patients with hereditary cancer syndromes associated with gastrointestinal cancer risk. 38(2020), (suppl 4; abstr 680).
    51. Baron K, Nevala-Plagemann CD, Moser J, Haaland B, Wang X, Garrido-Laguna (2020). Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma. 38(2020), (suppl 4; abstr 657).
    52. Vaishnavi A, Scherzer M, Kinsey C, Garrido-Laguna I, McMahon (2020). Combined TRKA and MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance in a New Preclinical Model of NTRK1+ Pancreatic Cancer.
    53. Braithwaite M, Nevala-Plagemann CD, Baron K, Haaland B, Pappas LM, Garrido-Laguna I (2020). Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States. 38(suppl; abstr 4030 American Society of Clinical Oncology Annual Meeting),
    54. Garrido-Laguna I, Dillon PM, Anthony SP, Janat-Amsbury M, Ashenbramer N, Warner SL, Mouritsen L, Wade ML, Whatcott C, Bearss D, Fu S (2020). A phase I, first-in-human, open-label, dose'escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP¿3654 administered daily for 28 days to patients with advanced solid tumors. May 2020,
    55. Meric-Bernstam F, Calvo E, Moreno V, Chung HC, Park YH, Bang Y-J, Rosen LS, Mita MM, Garrido-Laguna I, Leung ACF, Dube H, Zhong W, Chen X, Dawaher R, Curigliano G (2020). A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF¿06804103) in patients with HER2-positive solid tumors. 38(suppl; abstr 1039 American Society of Clinical Oncology Annual Meeting),
    56. Florou V, Nevala-Plagemann C, Barber K, Mastroianni J, Cavalieri C, Garrido-Laguna I (2020). Immune checkpoint inhibition re-challenge after a planned treatment interruption in patients with pancreatic adenocarcinoma with mismatch repair deficient tumors. (2021) 39(suppl_15 abstr), 2599.
    57. Florou V, Nevala-Plagemann C, Mulvihill S, Garrido-Laguna I (2020). Pancreatic acinar carcinoma - a rare entity with a targetable BRAF V600E mutation. Proceedings of the American Association for Cancer Research, June 2020,
    58. Sohal D, Duong MT, Chang R, Xue Y, Delman D, Garrido-Laguna I, Mulvihill SJ, Affolter K, Washington MK, Beg MS, Wang-Gillam A, Wade JL, Gandhi N, Ahmad SA, Lowy AM, Chiorean EG, Guthrie KA, Hochster HS, Philip PA, Beatty G (2021). Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505. 39(2021), (suppl 3; abstr 419).
    59. Miotke L, Nevala-Plagemann CD, Ying J, Florou V, Haaland B, Garrido-Laguna (2021). Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma. 39(2021), (suppl 3: abstr 387).
    60. Parsons M, Lloyd S, Johnson SB, Scaife CL, Garrido-Laguna I, Tao (2021). The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients. 39(2021), (suppl 3: abstr 291).
    61. Florou V, Floudas CS, Maoz A, Naqash AR, Hildebrand G, Sokol E, Frampton GM, Puri S, Swami U, Wilky BA, Hosein PJ, Trent JC, Lopes G, Park W, Garrido-Laguna (2021). Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB). 39(2021), (suppl 15: abstr 2599).
    62. Gardner F, Wainberg ZA, Fountzilas C, Bahary N, Womack M, Mercada TM, Garrido-Laguna I, Peterson PM, Ceccarelli M, Pelzer (2021). Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel &plusmn; olaratumab in treatment-na&iuml;ve patients with unresectable metastatic pancreatic cancer. 2021(32 suppl 5), S1084-S1095.
    63. Rodon J, Tan DSW, Garrido-Laguna I, Harb W, Beck JT, Bahary N, Rottey S, Zhu Z, Deng S. Kowalski K, O'Neill G, Wei C, Pathan N, Messersmith W (2021). Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial. 9(Suppl 2), A371.
    64. Abrams TA, Kazmi SMA, Winer IS, Subbiah V, Falchook GS, Reilley M, Kunk PR, Goel S, Garrido-Laguna I, Kochenderfer MD, Werneke S, Andrianova L, Sudhagoni R, Paulson (2022). A Phase 1b Multi-tumor Cohort Study of Cabozantinib Plus Atezolizumab in Advanced Solid Tumors (Cosmic -021): Results of the Colorectal Cancer Cohort. 40(4 Suppl), 121.
    65. Nevala-Plagemann CD, Ying J, Sama S, Florou V, Haaland B, Garrido-Laguna (2022). A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States. 40(4 Suppl), 39.
    66. Garrido-Laguna (2021). Phase 1, first-in-human, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advances solid tumors. 20(12_suppl), P223.
    67. Abrams TA, Kazmi SMA, Winer IS, Subbiah V, Falchook GS, Reilley M, Kunk RP, Goel S, Garrido-Laguna I, Kochenderfer MD, Werneke S, Andrianova L, Sudhagoni R, Paulson (2022). A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort. 40(4 Suppl), 121.

    Other

    1. Solomon BL, Garrido-Laguna (2018). Novel Therapies in Pancreatic Cancer: Opportunities and Challenges for Precision Medicine.

  • News & Podcasts

    News

    Huntsman Cancer Institute News